NAGE

Niagen Bioscience, Inc. Common Stock

NAGE

Market cap $766M

Overview Fund Activity

9.61 USD

-0.01

0.1%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

9.79

+0.18

1.87%

1 day

-0.1%

5 days

1.26%

1 month

-6.34%

3 months

-32.04%

6 months

22.73%

Year to date

75.36%

1 year

174.57%

5 years

107.56%

10 years

114.51%

About: Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

Employees: 104

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

196% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 25

143% more capital invested

Capital invested by funds: $172M [Q1] → $418M (+$246M) [Q2]

76% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 21

11% more funds holding

Funds holding: 139 [Q1] → 154 (+15) [Q2]

10% more call options, than puts

Call options by funds: $3.47M | Put options by funds: $3.14M

4.81% more ownership

Funds ownership: 32.02% [Q1] → 36.83% (+4.81%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$12

25% upside

Avg. target

$12

25% upside

High target

$12

25% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Raghuram Selvaraju

$12

Buy

Maintained

11 Aug 2025

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates

Niagen Bioscience (NAGE) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to break-even earnings per share a year ago.

Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 37% to $31.1 million, with Tru Niagen® sales reaching $22.7 million, growing 22%. Niagen® ingredient sales increased 135% to $7.4 million including food-grade and pharmaceutical-grade. Gross margin increased 480 basis points to 65.0%. Sales and marketing expense as a.

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity's 45th Annual Growth Conference, taking place from August 12 to 14, 2024, in Boston. Mr. Fried is scheduled to participate in a fireside chat on Tuesda.

Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, August 6, at 4:30 p.m. ET to discuss its financial results for the second quarter 2025, which ended June 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on W.

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the inaugural hotel debut of Tru Niagen® as an in-room amenity at the Equinox Hotel New York, and Niagen IV, now available at the hotel's spa through NutriDrip. Rob Fried, CEO of Niagen Bioscience, remarked, “Our partnership with Equinox Hotel and NutriDrip underscores our c.

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has entered into a worldwide exclusive commercial license agreement with the Haukeland University Hospital, Bergen, Norway. The agreement secures exclusive rights to a body of proprietary intellectual property, know-how, and data. These data are expected to support future.

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

Niagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic Trends

NAGE is a leader in the growing NAD+ supplement market, benefiting from rising health and longevity trends and strong brand awareness with its flagship Tru Niagen product. Analyst estimates for 2025 remain too low; further upside revisions look possible based on our alternative data channel checks. Our DCF valuation suggests at least 20% upside as a standalone company, and even more if viewed through the lens of a potential acquirer.

Niagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic Trends

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the Roth 15th Annual London Conference, which will be held at the Four Seasons Hotel London at Park Lane in London, UK on June 24-26, 2025. Niagen Bioscience CFO, Ozan Pamir, will attend in-person one-on-one meetings with institutio.

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

Niagen Bioscience to Participate in the BIO 2025 International Convention

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its participation in the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. Hosted by the Biotechnology Innovation Organization (BIO), the BIO International Convention is the world's largest and most influential biotechnology event, c.

Niagen Bioscience to Participate in the BIO 2025 International Convention

Niagen Bioscience: High Conviction, High Expectations

Niagen Bioscience's stock price is breaking out with strong fundamentals, proprietary IP, and a leadership position in the NAD+ longevity market. Revenue and margins are rising, driven by Tru Niagen e-commerce and pharma-grade injectables, with operating leverage and efficient marketing boosting profitability. Valuation is rich, reflecting high expectations for continued growth and clinical pipeline success, but execution risk is elevated at these multiples.

Niagen Bioscience: High Conviction, High Expectations

See News Rankings

Charts implemented using Lightweight Charts™